Drug Delivery: Transdermal Devices

Transdermal drug delivery refers to topically administered pharmaceutical preparations formulated to penetrate the skin and achieve a local or systemic therapeutic effect. In 2023, global sales of transdermal patch products targeting the conditions covered by this analysis totaled more than $2.8bn.

Market drivers include the rising prevalence of the disorders treated by these products as the population ages, improved patient compliance with patches compared to oral medication, and benefits of transdermal drug delivery such as eliminated first-pass metabolism. Limiters to this market include declines in mature market segments as a result of generic erosion, robust competition among generics manufacturers, legal and regulatory issues associated with certain product types, and strong competition from oral medications.

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for transdermal patches intended to treat cardiovascular disease (angina pectoris and hypertension), neurological disorders (Alzheimer’s disease, ADHD, major depressive disorder, and Parkinson’s disease), hormone replacement therapy (for the treatment of menopause and osteoporosis), and pain management.

Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2023–28.

If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].